File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hepatocellular carcinoma: recent advances and emerging medical therapies

TitleHepatocellular carcinoma: recent advances and emerging medical therapies
Authors
Keywordshepatocellular carcinoma
medical therapy
Issue Date2020
PublisherFaculty of 1000 Ltd. The Journal's web site is located at http://f1000research.com
Citation
F1000Research, 2020, v. 9, p. article no. 620 How to Cite?
AbstractHepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Major breakthroughs have been made over the past few years in the management of hepatocellular carcinoma, especially in medical therapies for advanced disease. In this article, recent advances in intra-arterial therapy, multi-kinase inhibitors, and immunotherapy will be reviewed.
Persistent Identifierhttp://hdl.handle.net/10722/284983
ISSN
2015 SCImago Journal Rankings: 0.560
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorKo, KL-
dc.contributor.authorMak, LY-
dc.contributor.authorCheung, KS-
dc.contributor.authorYuen, MF-
dc.date.accessioned2020-08-07T09:05:11Z-
dc.date.available2020-08-07T09:05:11Z-
dc.date.issued2020-
dc.identifier.citationF1000Research, 2020, v. 9, p. article no. 620-
dc.identifier.issn2046-1402-
dc.identifier.urihttp://hdl.handle.net/10722/284983-
dc.description.abstractHepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Major breakthroughs have been made over the past few years in the management of hepatocellular carcinoma, especially in medical therapies for advanced disease. In this article, recent advances in intra-arterial therapy, multi-kinase inhibitors, and immunotherapy will be reviewed.-
dc.languageeng-
dc.publisherFaculty of 1000 Ltd. The Journal's web site is located at http://f1000research.com-
dc.relation.ispartofF1000Research-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjecthepatocellular carcinoma-
dc.subjectmedical therapy-
dc.titleHepatocellular carcinoma: recent advances and emerging medical therapies-
dc.typeArticle-
dc.identifier.emailMak, LY: lungyi@hku.hk-
dc.identifier.emailCheung, KS: cks634@hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authorityMak, LY=rp02668-
dc.identifier.authorityCheung, KS=rp02532-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.12688/f1000research.24543.1-
dc.identifier.pmid32595940-
dc.identifier.pmcidPMC7308880-
dc.identifier.scopuseid_2-s2.0-85086875884-
dc.identifier.hkuros312203-
dc.identifier.volume9-
dc.identifier.spagearticle no. 620-
dc.identifier.epagearticle no. 620-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl2046-1402-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats